Abstract
Autoreactive B cells have critical roles in a large diversity of autoimmune diseases, but the molecular pathways that control these cells remain poorly understood. We performed an in vivo functional screen of a lymphocyte-expressed microRNA library and identified miR-148a as a potent regulator of B cell tolerance. Elevated miR-148a expression impaired B cell tolerance by promoting the survival of immature B cells after engagement of the B cell antigen receptor by suppressing the expression of the autoimmune suppressor Gadd45α, the tumor suppressor PTEN and the pro-apoptotic protein Bim. Furthermore, increased expression of miR-148a, which occurs frequently in patients with lupus and lupus-prone mice, facilitated the development of lethal autoimmune disease in a mouse model of lupus. Our studies demonstrate a function for miR-148a as a regulator of B cell tolerance and autoimmunity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
References
Shlomchik, M.J. Sites and stages of autoreactive B cell activation and regulation. Immunity 28, 18–28 (2008).
Goodnow, C.C., Sprent, J., Fazekas de St Groth, B. & Vinuesa, C.G. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 435, 590–597 (2005).
Nemazee, D. Receptor editing in lymphocyte development and central tolerance. Nat. Rev. Immunol. 6, 728–740 (2006).
Tiller, T. et al. Autoreactivity in human IgG+ memory B cells. Immunity 26, 205–213 (2007).
Wardemann, H. et al. Predominant autoantibody production by early human B cell precursors. Science 301, 1374–1377 (2003).
Kinnunen, T. et al. Specific peripheral B cell tolerance defects in patients with multiple sclerosis. J. Clin. Invest. 123, 2737–2741 (2013).
Samuels, J., Ng, Y.S., Coupillaud, C., Paget, D. & Meffre, E. Impaired early B cell tolerance in patients with rheumatoid arthritis. J. Exp. Med. 201, 1659–1667 (2005).
Yurasov, S. et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J. Exp. Med. 201, 703–711 (2005).
Bartel, D.P. MicroRNAs: target recognition and regulatory functions. Cell 136, 215–233 (2009).
Kuchen, S. et al. Regulation of microRNA expression and abundance during lymphopoiesis. Immunity 32, 828–839 (2010).
Monticelli, S. et al. MicroRNA profiling of the murine hematopoietic system. Genome Biol. 6, R71 (2005).
O'Connell, R.M., Rao, D.S., Chaudhuri, A.A. & Baltimore, D. Physiological and pathological roles for microRNAs in the immune system. Nat. Rev. Immunol. 10, 111–122 (2010).
Xiao, C. & Rajewsky, K. MicroRNA control in the immune system: basic principles. Cell 136, 26–36 (2009).
Chauhan, S.K., Singh, V.V., Rai, R., Rai, M. & Rai, G. Differential microRNA profile and post-transcriptional regulation exist in systemic lupus erythematosus patients with distinct autoantibody specificities. J. Clin. Immunol. 34, 491–503 (2014).
Pan, W. et al. MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4+ T cells by directly and indirectly targeting DNA methyltransferase 1. J. Immunol. 184, 6773–6781 (2010).
Stagakis, E. et al. Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: miR-21 regulates aberrant T cell responses through regulation of PDCD4 expression. Ann. Rheum. Dis. 70, 1496–1506 (2011).
Te, J.L. et al. Identification of unique microRNA signature associated with lupus nephritis. PLoS One 5, e10344 (2010).
Dai, R. et al. Identification of a common lupus disease-associated microRNA expression pattern in three different murine models of lupus. PLoS One 5, e14302 (2010).
Lindberg, R.L., Hoffmann, F., Mehling, M., Kuhle, J. & Kappos, L. Altered expression of miR-17-5p in CD4+ lymphocytes of relapsing-remitting multiple sclerosis patients. Eur. J. Immunol. 40, 888–898 (2010).
Qin, H.H. et al. The expression and significance of miR-17-92 cluster miRs in CD4+ T cells from patients with systemic lupus erythematosus. Clin. Exp. Rheumatol. 31, 472–473 (2013).
Simpson, L.J. et al. A microRNA upregulated in asthma airway T cells promotes TH2 cytokine production. Nat. Immunol. 15, 1162–1170 (2014).
Kang, S.G. et al. MicroRNAs of the miR-17∼92 family are critical regulators of T(FH) differentiation. Nat. Immunol. 14, 849–857 (2013).
Xiao, C. et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat. Immunol. 9, 405–414 (2008).
Luo, X. et al. A functional variant in microRNA-146a promoter modulates its expression and confers disease risk for systemic lupus erythematosus. PLoS Genet. 7, e1002128 (2011).
Tang, Y. et al. MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum. 60, 1065–1075 (2009).
Boldin, M.P. et al. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J. Exp. Med. 208, 1189–1201 (2011).
Hu, R. et al. miR-155 promotes T follicular helper cell accumulation during chronic, low-grade inflammation. Immunity 41, 605–619 (2014).
Lu, L.F. et al. Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell 142, 914–929 (2010).
Adams, B.D. et al. An in vivo functional screen uncovers miR-150-mediated regulation of hematopoietic injury response. Cell Rep. 2, 1048–1060 (2012).
Duong, B.H. et al. Negative selection by IgM superantigen defines a B cell central tolerance compartment and reveals mutations allowing escape. J. Immunol. 187, 5596–5605 (2011).
Lu, R., Neff, N.F., Quake, S.R. & Weissman, I.L. Tracking single hematopoietic stem cells in vivo using high-throughput sequencing in conjunction with viral genetic barcoding. Nat. Biotechnol. 29, 928–933 (2011).
Haftmann, C. et al. miR-148a is upregulated by Twist1 and T-bet and promotes Th1-cell survival by regulating the proapoptotic gene Bim. Eur. J. Immunol. 45, 1192–1205 (2015).
Dai, R. et al. Sex differences in the expression of lupus-associated miRNAs in splenocytes from lupus-prone NZB/WF1 mice. Biol. Sex Differ. 4, 19 (2013).
Scott, D.W., Livnat, D., Pennell, C.A. & Keng, P. Lymphoma models for B cell activation and tolerance. III. Cell cycle dependence for negative signalling of WEHI-231 B lymphoma cells by anti-mu. J. Exp. Med. 164, 156–164 (1986).
Scott, D.W. et al. Lymphoma models for B-cell activation and tolerance. II. Growth inhibition by anti-mu of WEHI-231 and the selection and properties of resistant mutants. Cell. Immunol. 93, 124–131 (1985).
Bouillet, P. et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 286, 1735–1738 (1999).
Erickson, S.L. et al. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 372, 560–563 (1994).
Lesche, R. et al. Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis 32, 148–149 (2002).
Rickert, R.C., Roes, J. & Rajewsky, K. B lymphocyte-specific, Cre-mediated mutagenesis in mice. Nucleic Acids Res. 25, 1317–1318 (1997).
Salvador, J.M. et al. Mice lacking the p53-effector gene Gadd45a develop a lupus-like syndrome. Immunity 16, 499–508 (2002).
Enders, A. et al. Loss of the pro-apoptotic BH3-only Bcl-2 family member Bim inhibits BCR stimulation-induced apoptosis and deletion of autoreactive B cells. J. Exp. Med. 198, 1119–1126 (2003).
Cheng, S. et al. BCR-mediated apoptosis associated with negative selection of immature B cells is selectively dependent on Pten. Cell Res. 19, 196–207 (2009).
Andrews, B.S. et al. Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J. Exp. Med. 148, 1198–1215 (1978).
Shen, N., Liang, D., Tang, Y., de Vries, N. & Tak, P.P. MicroRNAs--novel regulators of systemic lupus erythematosus pathogenesis. Nat. Rev. Rheumatol. 8, 701–709 (2012).
Di Cristofano, A. et al. Impaired Fas response and autoimmunity in Pten+/- mice. Science 285, 2122–2125 (1999).
Oliver, P.M., Vass, T., Kappler, J. & Marrack, P. Loss of the proapoptotic protein, Bim, breaks B cell anergy. J. Exp. Med. 203, 731–741 (2006).
Browne, C.D., Del Nagro, C.J., Cato, M.H., Dengler, H.S. & Rickert, R.C. Suppression of phosphatidylinositol 3,4,5-trisphosphate production is a key determinant of B cell anergy. Immunity 31, 749–760 (2009).
Salvador, J.M., Brown-Clay, J.D. & Fornace, A.J. Jr. Gadd45 in stress signaling, cell cycle control, and apoptosis. Adv. Exp. Med. Biol. 793, 1–19 (2013).
Salvador, J.M., Mittelstadt, P.R., Belova, G.I., Fornace, A.J. Jr. & Ashwell, J.D. The autoimmune suppressor Gadd45alpha inhibits the T cell alternative p38 activation pathway. Nat. Immunol. 6, 396–402 (2005).
Tong, T. et al. Gadd45a expression induces Bim dissociation from the cytoskeleton and translocation to mitochondria. Mol. Cell. Biol. 25, 4488–4500 (2005).
Acknowledgements
We thank D. Kono for advice on the analysis of MRL-lpr mice; L. Sherman (The Scripps Research Institute, La Jolla) for Bcl2l11−/− mice; members of the Xiao and Nemazee laboratories for advice and technical assistance; and the TSRI Flow Cytometry and Genomics Core Facilities for support. Supported by the Pew Charitable Trusts (C.X.), the Cancer Research Institute, the Lupus Research Institute and the US National Institutes of Health (R01 AI089854 to C.X.; R01 AI59714 to D.N.; and RC4 AI092763 to C.X. and D.N.).
Author information
Authors and Affiliations
Contributions
A.G.-M., D.N. and C.X. conceptualized and designed the project, and wrote the manuscript with contributions from all authors; A.G.-M. performed most of the experiments; B.D.A. and J.L. provided the retroviral miRNA-expression library for pool screen and retroviral vectors encoding individual miRNAs for validation of positive 'hits', and performed miRNA barcode analysis to identify miRNAs that broke B cell tolerance; M.L. performed bone marrow–reconstitution experiments with Bim- or PTEN-deficient mice; J.S. managed the mouse colony and provided technical support; M.S.-B. and J.M.S. bred Gadd45α-deficient mice, harvested bones and shipped these for bone marrow–reconstitution experiments; and D.N. and C.X. supervised the project.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Integrated supplementary information
Supplementary Figure 1 Barcode analysis for the identification of miRNAs that break B cell tolerance.
(a) Barcode identification method. Genomic DNA samples from purified splenic B cells that escaped tolerance in the IgMb-macroself recipient mice and bone marrow B cell precursors from the same mice were subjected to a universal PCR that amplified the miRNA cassette of this retroviral library. PCR products were hybridized with barcode probes coupled to specific beadsets and subsequently incubated with SA-PE. Samples were analyzed by flow cytometry for barcode identification. Adapted from reference 29. (b,c) Log2 signal distribution of a water control (b) and experimental samples (c). The background noise is represented by values lower than 7 in the x-axis. Values greater than 7 represent miRNAs that were encoded by retroviruses integrated into the genomes of B cells and drove their escape from the central tolerance checkpoint imposed by the IgMb-macroself superantigen.
Supplementary Figure 2 No synergistic effect between miRNAs that break B cell tolerance in IgMb-macroself mice.
(a) Representative FACS plots showing splenic B cells (CD19+IgM+) in IgMb-macroself mice reconstituted with HSPCs infected with control, miR-148a or a mixture of 6 different retroviruses encoding miRNAs identified in the screen (miR-148a, -26a, -26b, -342, -423, -511) at terminal analysis. (b,c) Percentages (b) and numbers (c) of splenic B cells in mice analyzed in a. Data are pooled from four individual experiments (a-c; mean ± s.e.m. in b-c): n=3 mice in control and retroviral miR-148a, -26a, -26b, -342, -423, -511 mixture and n=6 mice in miR-148a group.
Supplementary Figure 3 miR-148a expression during the development and activation of B cells.
(a) Small RNA deep sequencing analysis showing miR-148a expression in murine B lineage cells at various development and activation stages. The graph was generated based on previously published data10. (b) Taqman microRNA assay showing miR-148a expression in purified B cells in the absence of stimulation or stimulated with 10μg/ml anti-IgM, 10μg/ml LPS or 10μg/ml anti-IgM + 10μg/ml LPS as indicated. Data are representative of two independent experiments (b; mean ± s.d. of technical triplicates).
Supplementary Figure 4 TNFR2 does not have a major role in controlling B cell central tolerance.
(a) FACS analysis showing TNFR2 surface expression of non-stimulated and stimulated (2μg/ml anti-IgM for 14h) WEHI-control, WEHI-miR-148a, WEHI-miR-26a and WEHI-miR-182 cells. (b) Representative FACS plots showing splenic B cells (CD19+IgM+) at terminal analysis of IgMb-macroself recipient mice reconstituted with bone marrow cells from mice of the indicated genotypes. (c,d) Percentages (c) and numbers (d) of splenic B cells in mice analyzed in b. Data are representative of two independent experiments (a) or pooled from two individual experiments (b-d; mean ± s.e.m. in c,d): n=5 mice in control and n=6 mice in Tnfrsf1b-/- group. Statistical analysis was performed with a two-tailed Student’s T test. ** P<0.01.
Supplementary Figure 5 miR-148a, but not miR-26a or miR-182, regulates the expression of Bim, PTEN and Gadd45 simultaneously.
(a) qRT-PCR analysis showing target gene mRNA expression of WEHI-control, WEHI-miR-148a, WEHI-miR-26a and WEHI-miR-182 stimulated with anti-IgM (2μg/ml) for 14 h. (b) Western blot analysis showing miR-148a target gene expression in stimulated (2μg/ml anti-IgM for 14 h) WEHI-control, WEHI-miR-148a, WEHI-miR-26a and WEHI-miR-182. The target gene protein/β-actin ratio in the control samples was arbitrarily set as 1. Data are pooled from two individual experiments (a; mean ± s.d.) or pooled from two or three individual experiments for Bim and PTEN respectively (b; mean ± s.d.). Statistical analysis was performed with a two-tailed Student’s T test. *P<0.05, ** P<0.01.
Supplementary Figure 6 B cell–activation status and miR-148a expression in young MRL-lpr mice, and overexpression of miR-148a achieved by a retroviral vector.
(a) FACS analysis showing B cell activation marker CD69 staining of splenic B cells of 6 week-old control and MRL-lpr mice. LPS-activated B cells (10μg/ml for 20h) were included as a positive control. (b) Taqman microRNA assay showing miR-148a expression in splenic B cells from the control and MRL-lpr mice. Data are representative of two independent experiments (a) or pooled from two independent experiments (b; mean ± s.e.m.): n=3 mice/group. (c) Taqman microRNA assay showing miR-148a expression in splenic B cells purified from MRL-lpr recipient mice in experiments described in Figure 6. The average miR-148a expression level of the control group was arbitrarily set as 1. Data are pooled from two independent experiments: n=6 mice in control and n=7 mice in miR-148a group. Statistical analysis was performed with a two-tailed Student’s T test. ** P<0.01.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–6 and Supplementary Tables 1 and 2 (PDF 1306 kb)
Source data
Rights and permissions
About this article
Cite this article
Gonzalez-Martin, A., Adams, B., Lai, M. et al. The microRNA miR-148a functions as a critical regulator of B cell tolerance and autoimmunity. Nat Immunol 17, 433–440 (2016). https://doi.org/10.1038/ni.3385
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ni.3385
This article is cited by
-
MicroRNA as a potential biomarker for systemic lupus erythematosus: pathogenesis and targeted therapy
Clinical and Experimental Medicine (2023)
-
The emerging role non-coding RNAs in B cell-related disorders
Cancer Cell International (2022)
-
Systematic characterization of seed overlap microRNA cotargeting associated with lupus pathogenesis
BMC Biology (2022)
-
MiR-148a deletion protects from bone loss in physiological and estrogen-deficient mice by targeting NRP1
Cell Death Discovery (2022)
-
Autoimmunity and organ damage in systemic lupus erythematosus
Nature Immunology (2020)